GSK today announced that the US Food and Drug Administration (FDA) has approved, under priority review, the use of the intravenous (IV) formulation of Benlysta (belimumab), a B-lymphocyte stimulator (BLyS)-specific inhibitor, in children with lupus from as young as five years of age.
{iframe}https://pipelinereview.com/index.php/2019042871110/Antibodies/GSK-receives-US-approval-of-Benlysta-for-intravenous-use-in-children-with-lupus-aged-five-years-and-above.html{/iframe}